Cid Cabillan

Engagement with the Government regarding the Life Science Fund seeking partnership and funding to support completion of Phase I and Phase II clinical research program associated to AMR (antimicrobial resistance) Antimicrobial Resistance (AMR) - Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. Also discuss any applicable conditions regarding this funding. Programs and policy to support Canadian biomanufacturing and access to medicines and vaccines for Canadians. National Immunization Strategy and policies and programs that impact public access to vaccines and disease prevention in Canada. Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy and policies and programming related to biomanufacturing in Canada Access to medicines - government policies, processes, legislation, and/or regulation with potential impact on access to medicines in Canada. Trade-related matters, including policies and tariffs impacting medicines and vaccines. Policies and programs related to the health of new immigrants to Canada. Policies, programs, and funding related to Canada's Sexually Transmitted and Blood-Borne Infections (STBBI) Action Plan 2024-2030. Engagement with federal officials regarding Health Emergency Readiness Canada. The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004. Advocacy for ways to increase access to medicines and vaccines for Canadian patients. The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada. Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR. Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage. Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts. Public Services and Procurement Canada (PSPC) Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework. Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment. Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development. Legislation, regulations, policies and programs concerning the federal government's response to COVID-19, including pandemic preparedness, pharmaceutical and vaccine supply-chain management, and general administration of justice. Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process. Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions. FedDev Ontario Advanced Manufacturing Fund - advancing manufacturing of innovative pharmaceutical products in southern Ontario Engage with government to strengthen the Priority Review for Drug Submissions process. Engage the Government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians. Engagement with the Government regarding the Strategic Innovation Fund Drug Re-importation - Raise awareness regarding the potential risks to drug and vaccine supply fo

Engage with government to strengthen the Priority Review of Drug Submissions process. The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements. Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines. Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors. Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada. Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation. Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development. Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines. Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace. Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs. Engage the government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians. Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine. Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.

Engage with government to strengthen the Priority Review of Drug Submissions process. The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements. Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines. Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors. Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada. Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation. Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development. Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines. Harmonizing rules for the sampling of natural health products under the proposed Canada-United States-Mexico trade agreement. Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace. Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs. Engage the government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians. Engagement with government officials on disruptions to business, health & safety requirements, and opportunities to help with the COVID-19 pandemic. Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine. Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR. Allow for the regulation of products containing cannabidiol (CBD) as natural health products.

Building awareness in government of technological advancements in integrating crednetial authentication technology at security checkpoints across borders, airports, etc. to faciltiate passenger identity verification and transport.

Advocate to government for justice and truth for victims of flight PS752 and their families.

Implementation of the Homelessness Reduction Innovation Fund Expand funding for community efforts to address homelessness through Reaching Home and make changes to the National Housing Strategy, Reaching Home, and federal housing policy to support ending homelessness and the implementation of the right to housing in Canada. Seeking to secure federal government investment in affordable and supportive housing for Canadians experiencing or at risk of homelessness and expand housing options for people at risk of or experiencing homelessness through Build Canada Homes. Policies and investments in support of ending homelessness in Budget 2026 Taxation relating to Canadian charities Seeking program and policy changes from Women and Gender Equity to address housing need and homelessness for women. Seeking program and policy changes from Veterans Affairs Canada and Housing Infrastructure and Communities Canada to support federal action on ending homelessness for veterans. Seeking funding support for National Conference on Ending Homelessness, funding to support work to prevent and reduce homelessness as well as funding for research on homelessness and housing need in Canada, through Reaching Home (HICC); Veterans Affairs Canada; Canada Mortgage Housing Corporation; and Women & Gender Equality, to support research on homelessness for women and advancing the right to housing. Encouraging the implementation of housing policies in alignment with the human right to housing and National Housing Strategy Act

-Seeking funding for proposed training and farm innovations for workers and farm employers. -Proposed Agriculture and Agri-Food Workforce Action Plan and Workforce Program, to increase the labour supply and to increase training for the agriculture sector workers and employers. -Address agriculture labour issues and shortages with government officials by seeking support for the implementation of Agri-Food Immigration Pilot that will allow immigration access for farm and food workers, also create new incentives to encourage refugees and new immigrants to work on farms and to also address the Temporary Foreign Worker Program application process issues with administrative efficiencies.

The Ontario Personal Support Worker Association may communicate with public office holders regarding labour and health policies in Budget 2022.

Transportation - proposed new international bilateral air routes with Canada. Consideration of airport rents at formerly owned federal airports across Canada. Tourism - Canadian Tourism Commission Budget as announced in the 2010 Federal Budget. Development of the proposed Federal Tourism Strategy as announced by the Prime Minister in June 2009. Taxation and Finance - Ammendments to the Foreign Convention Tour and Incentive Program. Regulations and policies regarding fees to SOCAN and Re:Sound Immigration Canada - Support for Temporary Foreign Workers Program. Engage with the Federal Government on proposed new or amended taxation laws with respect to short-term accommodations. Employment and Training - Support for the Temporary Foreign Workers Program. Criminal Code regulations pertaining to impaired driving Coronavirus (COVID-19) Pandemic - Seeking changes on EI reform. Ensuring access to financial impact measures. Monitoring developments and assessing impacts on members.

Exchange information regarding Canadian citizenship uptake; increase awareness on Institute for Canadian Citizenship programming; building capacity for Institute for Canadian Citizenship; and creating opportunities.

Seeking sustainable, long-term funding from the federal government in the form of a grant, for a training program for individuals from underserved communities in the information technology sector. The funds will be used to hire educators, pay salaries, and purchase equipment for the delivery of the program.

Changes to immigration pathways and programs including Express Entry; provision of employment and settlement supports for international students, refugees, and immigrants; removal of barriers to licensing of internationally educated health professionals; Canada's international education strategy;